Author

Akbar Abdollahi Asl

Tehran University of Medical Sciences - Cited by 460 - Pharmacoeconomics and pharmaceutical administration

Biography

Akbar Abdollahi Asl is an Experienced Assistant Professor with a demonstrated history of working in the higher education industry. Skilled in Business Planning, Market Analysis, and Healthcare Information Technology (HIT). Administrative professional with a Doctor of Philosophy (PhD) focused in pharmacoeconomics and Pharmaceutical administration from Tehran University of Medical sciences.
Title
Cited by
Year
Pharmaceutical supply chain risks: a systematic review
M Jaberidoost, S Nikfar, A Abdollahiasl, R DinarvandDARU Journal of Pharmaceutical Sciences 21, 1-7, 2013201
129
2013
Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries
A Kebriaeezadeh, NN Koopaei, A Abdollahiasl, S Nikfar, N MohamadiDARU journal of pharmaceutical Sciences 21, 1-8, 2013201
76
2013
Cost and utilization study of antidotes: an Iranian experience.
S Nikfar, M Khatibi, A Abdollahi-Asl, M AbdollahiInternational Journal of Pharmacology 7 (1), 46-49, 2011201
44
2011
Patterns of antibiotic consumption in Iran during 2000-2009.
A Abdollahiasl, A Kebriaeezadeh, S Nikfar, A Farshchi, G Ghiasi, ...International journal of antimicrobial agents, 2011201
43
2011
A system dynamics model for national drug policy
A Abdollahiasl, A Kebriaeezadeh, R Dinarvand, M Abdollahi, ...Daru journal of pharmaceutical sciences 22, 1-13, 2014201
27
2014
Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions
A Abdollahias, S Nikfar, M AbdollahiMed. Sci 7, 365-367, 2011201
14
2011
Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies
MA Rezvanfar, A Kebriaeezadeh, M Moein, S Nikfar, Z Gharibnaseri, ...Journal of research in pharmacy practice 2 (4), 162, 2013201
12
2013
An overview to pharmaceutical financing in Iran
M Varmaghani, A Hashemi-Meshkini, A Abdollahiasl, E Heidari, HS Zekri, ...Journal of Pharmacoeconomics and Pharmaceutical Management 2 (1/2), 45-49, 2016201
12
2016
Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
Z Gharibnaseri, A Kebriaeezadeh, S Nikfar, G Zamani, A AbdollahiaslDARU Journal of Pharmaceutical Sciences 20, 1-6, 2012201
9
2012
Availability, pricing and affordability of selected medicines for noncommunicable diseases
E Heidari, M Varmaghani, A AbdollahiaslEastern Mediterranean Health Journal 25 (7), 473-480, 20120
9
2019
Efficacies of regulatory policies to control massive use of diphenoxylate
A Farshchi, M Jaberidoost, A Abdollahiasl, M AbdollahiINTERNATIONAL JOURNAL OF PHARMACOLOGY 8 (5), 459-462, 2012201
7
2012
PHP41 Risk management in iranian pharmaceutical companies to ensure accessibility and quality of medicines
M Jaberidoost, A Abdollahiasl, A Farshchi, R DinarvandValue in Health 15 (7), A1-A17, 2012201
6
2012
Why healthcare market needs government intervention to improve access to essential medicines and healthcare efficiency: a scoping review from pharmaceutical price regulation …
M Mensa Sorato, M Davari, A Abdollahi Asl, F Soleymani, ...Journal of Pharmaceutical Health Services Research 11 (4), 321-333, 2020202
6
2020
An evaluation of policies and procedures of successful pharmaceutical exporters and the comparison of Iranian counterpart policy
M Seyedifar, S Nikfar, A Abdollahi-Asl, HR Rasekh, A Ehsani, ...Journal of Pharmacoeconomics and Pharmaceutical Management 1 (3/4), 39-44, 2015201
6
2015
A new approach in identifying and evaluating quality risks in the pharmaceutical industry
M Hajimolaali, A Kebriaeezadeh, A Abdollahiasl, H Safari, A YektadoostJournal of Pharmacoeconomics and Pharmaceutical Management 3 (1/2), 17-20, 2017201
5
2017
Pharmaceutical subsidy policy in Iran: a qualitative stakeholder analysis
A Olyaaeemanesh, E Jaafaripooyan, A Abdollahiasl, M Davari, ...Health Research Policy and Systems 19, 1-17, 2021202
5
2021
Quality risk assessment production of beta lactams by FMEA model and fuzzy theory method
M Hajimolaali, AA AslGeneral Medicine: Open Access (1), 1-3, 2016201
4
2016
PHP25 market analysis of antibiotics consumption in northern part of Iran during 2001-2010
P Zaboli, S Ala, AK Zadeh, A Abdollahiasl, S NikfarValue in Health 15 (7), A613-A61, 2012201
4
2012
PHP13 Affordability of antibacterial medicines in Iran during 2001-2010
A Abdollahiasl, M Jaberidoost, A FarshchiValue in Health 15 (7), A611, 2012201
4
2012
Healthcare resource utilization and cost of care for Gaucher patients in Iran
M Davari, A Nabizadeh, M Kadivar, A Abdollahiasl, P SarkheilJournal of Diabetes & Metabolic Disorders 18 (1), 127-12, 2019201
3
2019

Referred From: https://scholar.google.com/citations?user=PJ_ccOQAAAAJ&hl=en

Cited by
Citations 460
h-index 10
i10-index 10
Open Access Journals